Key Takeaways
- The framework used to evaluate products under the EU Health Technology Assessment (HTA) Regulation might pose unique challenges for vaccines, industry warns.
EU-level joint clinical assessments (JCAs) will apply for vaccines under the HTA Regulation from 2030, but manufacturers are concerned that...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?